Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPT NASDAQ:KRYS NYSE:RDY NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$21.03+0.3%$15.37$9.96▼$21.31$3.36B2.162.22 million shs103,555 shsKRYSKrystal Biotech$370.65-0.4%$304.72$130.50▼$376.28$11.00B0.53306,356 shs7,374 shsRDYDr. Reddy's Laboratories$14.85-3.5%$13.50$12.19▼$15.67$12.35B0.272.24 million shs123,034 shsSMMTSummit Therapeutics$14.39+2.7%$17.44$12.55▼$30.98$11.25B-1.323.96 million shs243,293 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies0.00%+19.55%+38.44%+63.22%+77.90%KRYSKrystal Biotech0.00%+6.95%+20.46%+50.75%+168.04%RDYDr. Reddy's Laboratories0.00%+15.53%+12.77%+14.27%+2.16%SMMTSummit Therapeutics0.00%+1.89%-20.13%-17.49%-31.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$21.03+0.3%$15.37$9.96▼$21.31$3.36B2.162.22 million shs103,555 shsKRYSKrystal Biotech$370.65-0.4%$304.72$130.50▼$376.28$11.00B0.53306,356 shs7,374 shsRDYDr. Reddy's Laboratories$14.85-3.5%$13.50$12.19▼$15.67$12.35B0.272.24 million shs123,034 shsSMMTSummit Therapeutics$14.39+2.7%$17.44$12.55▼$30.98$11.25B-1.323.96 million shs243,293 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies0.00%+19.55%+38.44%+63.22%+77.90%KRYSKrystal Biotech0.00%+6.95%+20.46%+50.75%+168.04%RDYDr. Reddy's Laboratories0.00%+15.53%+12.77%+14.27%+2.16%SMMTSummit Therapeutics0.00%+1.89%-20.13%-17.49%-31.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.57Moderate Buy$20.33-3.29% DownsideKRYSKrystal Biotech 2.83Moderate Buy$340.56-8.12% DownsideRDYDr. Reddy's Laboratories 1.67ReduceN/AN/ASMMTSummit Therapeutics 2.47Hold$27.2389.26% UpsideCurrent Analyst Ratings BreakdownLatest ADPT, RDY, SMMT, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026ADPTAdaptive Biotechnologies GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/18/2026KRYSKrystal Biotech TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$306.00 ➝ $403.006/17/2026ADPTAdaptive Biotechnologies BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.006/16/2026KRYSKrystal Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)6/16/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$310.00 ➝ $361.006/11/2026RDYDr. Reddy's Laboratories Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)6/1/2026SMMTSummit Therapeutics KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/1/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.005/29/2026RDYDr. Reddy's Laboratories Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)5/22/2026SMMTSummit Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/22/2026SMMTSummit Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$295.41M11.39N/AN/A$1.47 per share14.30KRYSKrystal Biotech$417.30M26.18$7.26 per share51.06$42.06 per share8.81RDYDr. Reddy's Laboratories$3.58B3.46$0.82 per share18.16$4.86 per share3.05SMMTSummit TherapeuticsN/AN/AN/AN/A$0.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$59.50M-$0.33N/AN/AN/A-16.82%-40.06%-16.64%8/4/2026 (Estimated)KRYSKrystal Biotech$204.83M$7.4849.8835.27N/A53.92%19.25%17.62%8/3/2026 (Estimated)RDYDr. Reddy's Laboratories$456M$0.5825.5122.842.1212.90%12.34%8.24%7/22/2026 (Estimated)SMMTSummit Therapeutics-$1.08B-$1.60N/AN/AN/AN/A-291.24%-243.07%8/10/2026 (Estimated)Latest ADPT, RDY, SMMT, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/22/2026Q1 26/27RDYDr. Reddy's Laboratories$0.1003N/AN/AN/A$830.50 millionN/A5/12/2026Q4 25/26RDYDr. Reddy's Laboratories$0.09$0.06-$0.03-$0.03$886.58 million$852.55 million5/5/2026Q1 2026ADPTAdaptive Biotechnologies-$0.16-$0.13+$0.03-$0.13$61.03 million$70.87 million5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 million5/1/2026Q1 2026SMMTSummit Therapeutics-$0.2692-$0.24+$0.0292-$0.24$0.05 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.070.47%+6.96%12.07%N/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A3.353.22KRYSKrystal BiotechN/A9.469.06RDYDr. Reddy's Laboratories0.031.801.34SMMTSummit TherapeuticsN/A7.417.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%KRYSKrystal Biotech86.29%RDYDr. Reddy's Laboratories3.85%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies5.70%KRYSKrystal Biotech13.10%RDYDr. Reddy's Laboratories2.00%SMMTSummit Therapeutics83.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790160.04 million150.92 millionOptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionableRDYDr. Reddy's Laboratories27,527834.66 million817.97 millionOptionableSMMTSummit Therapeutics110776.16 million128.07 millionOptionableADPT, RDY, SMMT, and KRYS HeadlinesRecent News About These CompaniesSummit Therapeutics: High-Volatility, Catalyst-Driven Binary BetJune 22, 2026 | seekingalpha.comSummit Therapeutics PLC $SMMT Shares Bought by Baker BROS. Advisors LPJune 18, 2026 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) CEO Mahkam Zanganeh Purchases 3,810,000 SharesJune 13, 2026 | insidertrades.comSummit Therapeutics PLC $SMMT Shares Bought by Polymer Capital Management HK LTDJune 13, 2026 | marketbeat.comWhy is SMMT stock tumbling today?June 10, 2026 | msn.comNorges Bank Takes $24.03 Million Position in Summit Therapeutics PLC $SMMTJune 10, 2026 | marketbeat.comSummit Therapeutics Announces Proposed Public Offering of Common StockJune 9, 2026 | businesswire.comSummit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comTD Asset Management Inc Increases Stock Position in Summit Therapeutics PLC $SMMTJune 8, 2026 | marketbeat.comMizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform TechJune 7, 2026 | 247wallst.comThe Era of the One-Size-Fits-All Cancer Drug Is EndingJune 6, 2026 | wsj.comSummit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial DataJune 5, 2026 | finance.yahoo.comSummit Therapeutics (NASDAQ:SMMT) CFO Manmeet Singh Soni Buys 50,000 SharesJune 5, 2026 | insidertrades.comSummit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare ConferenceJune 4, 2026 | businesswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT)June 4, 2026 | theglobeandmail.comAssessing Summit Therapeutics (SMMT) Valuation After A Mixed Share Price And Long Term Return ProfileJune 4, 2026 | finance.yahoo.comAll You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to BuyJune 4, 2026 | zacks.comSummit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology Congress - SlideshowJune 3, 2026 | seekingalpha.comCantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical DevelopmentsJune 2, 2026 | insidermonkey.comSummit Therapeutics (SMMT) Sheds 10.4%, This Analyst is PessimisticJune 2, 2026 | insidermonkey.comSummit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology Congress TranscriptJune 1, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADPT, RDY, SMMT, and KRYS Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$21.02 +0.07 (+0.31%) As of 09:55 AM Eastern This is a fair market value price provided by Massive. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Krystal Biotech NASDAQ:KRYS$370.65 -1.60 (-0.43%) As of 09:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Dr. Reddy's Laboratories NYSE:RDY$14.84 -0.54 (-3.48%) As of 09:55 AM Eastern This is a fair market value price provided by Massive. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Summit Therapeutics NASDAQ:SMMT$14.38 +0.38 (+2.68%) As of 09:55 AM Eastern This is a fair market value price provided by Massive. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback Winnebago Misses Estimates, But Surges 14% After Earnings 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right Now Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout 3 Stocks That Could Benefit as the Robotaxi Race Heats Up Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
